When: 10 EMA reclaim at $145.50 with MACD histogram turning positive within 3 sessions OR RSI 60 with price holding above $143

Then: Re-engage/trade add with Hold-to-Overweight sizing

HOLD the existing position; do not add at current levels ($144.81); prepare to add with measured sizing only in the $137 to $140 zone if printed; maintain hard stop at $137.74

• $151.22 resistance is the recent swing high and $137.74 is the 50 SMA defining technical anchor for the rally off June lows
• Three FDA approvals in four months drove the stock from $130 to $151.22 (~16% in 22 sessions), already pricing in the catalyst stack
• MACD bearish cross and price below 10 EMA signal momentum has shifted; light volume on pullback may indicate no bid rather than healthy consolidation
• Net debt increased from ~$17 billion to ~$23 billion ($11.21B acquisition + $4.07B new long-term debt); debt-to-EBITDA at 1.7x is manageable but direction is wrong
• PEG of 2.02 is stretched; forward P/E of 14.6x reasonable on normalized basis but stock is in upper third of 52-week range
• 93% probability of no Fed cuts is already priced in; if probability slips on hot CPI print, biotech beta will unwind in risk-off rotations
• $137.74 stop at the 50 SMA is the level where the trade thesis is invalidated, not an arbitrary percentage below entry

→ vs aggressive: The 1:1 risk/reward is not 'tape-reading' but measuring structural setup between current price and meaningful inflection points at $151.22 resistance and $137.74 support; moving averages work because they become self-fulfilling liquidity zones

HOLD existing position with conditional tactical flexibility; add only if price bases in $137-$140 zone with MACD histogram flattening/turning positive and at least two closes holding the 50 SMA; position sizing on any add should reflect HOLD to OVERWEIGHT transition, not full BUY

• Risk-reward is symmetric: 4.4% upside to $151.22 versus 4.9% downside to 50 SMA at $137.74, essentially a 1:1 reward-to-risk ratio
• At $144.81 after a 16% rally in 22 sessions, fundamentals have largely caught up to price rather than lagging it
• Fundamental thesis is intact: FDA approval cadence is real, HIV franchise durability is real, FCF yield at 5.4% is real, defensive characteristics are real
• Technical signals have information content: MACD bearish cross, price below 10 EMA and VWAP, three consecutive red days on declining volume signal current demand/supply imbalance
• Balance sheet deterioration is real capital constraint: equity nearly halved from $11B cash plus $4B new debt acquisition, debt-to-EBITDA at 1.7x materially higher than year ago
• Conservative analyst's February 2026 high comparison is a poor analog: RSI has reset to 52, MACD not deeply negative, stock has had base vs. all-time high overbought conditions then
• The add zone at $137-$140 should be conditioned on a basing pattern (2+ closes holding 50 SMA with MACD flattening), not just price tag—if price slices through on heavy volume, that is a trend break not a buy
• Stop at $137.74 should be closing-basis rather than intraday to avoid being shaken out on noise wicks while still protecting against real breakdowns
• Macro soft landing with no cuts supports cash-generative dividend payers like GILD but scenario is largely priced in and can flip on hot CPI data

→ vs aggressive: Fundamentals lagging price narrative is a post-hoc rationalization—the 16% rally in 22 sessions from August lows has largely closed any gap; calling a stock 'accelerating faster than price' at $144.81 in the upper third of its 52-week range after that run is motivated reasoning

→ vs aggressive: Dismissal of technical signals as 'noise' ignores real information content: MACD bearish cross, price below 10 EMA and VWAP, and 3 consecutive red days can signal early distribution if catalyst stack fails; treating conflicting signals as noise to ignore is how traders get caught loading up before a gap down

→ vs aggressive: Balance sheet impairment framing is too dismissive—even if impairment is non-cash, equity is gone because underlying assets are gone or written down; $11B cash plus $4B new debt deployment is real capital at risk, not a free option; debt-to-EBITDA at 1.7x reduces capital flexibility and increases refinancing risk

→ vs conservative: February 2026 high is a poor cautionary analog: that setup was at all-time highs with no base, MACD overbought, RSI extended, full premium priced in; current setup has RSI at 52, MACD rolled but not deeply negative, and stock has had a pullback—the market does not repeat setups exactly and cherry-picking a previous high is lazy analysis

→ vs conservative: 'Market priced in catalysts' efficient-market argument works until it doesn't; IBB beating S&P by 22 points in 3 months represents a real rotation that does not evaporate after 3 days of digestion; treating a normal pullback as evidence the rotation is over is premature

→ vs conservative: Hard rule requiring confirmed close above $147 with MACD positive before adding is too rigid—if stock bases between $140-$147 for 2 weeks without ever printing that signal and then rips to $155 on earnings, the move is entirely missed; demanding VIX of zero before adding is a recipe for never acting

→ vs conservative: PEG of 2.02 is elevated but not wildly expensive in a sector with mid-single-digit growth rates; stock being in upper third of 52-week range is a descriptive statistic about past performance, not a forecast of future underperformance